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Cel Med ated Cytotoxicity Expressed by
Lymphoid Cells from Rats with Asbestos
Induced Peritoneal Mesothelioma
towards Rat Fetal Cell
by R. H. Stevens,* D. A. Cole,* H. F. Cheng,*
J. A. Hodge* and L. A. WVilt
Cell-mediated immunity (CMI) directed towards rat fetal cells was evaluated in Fischer F344
young inbred male rats having asbestos-induced peritoneal mesothelioma. The tumors were induced
by exposure to Canadian chrysotile B fibers and the CMI delineated by the injury and destruction
brought about to 6- to 10-day-old primary fetal cell cultures by the so-called educated peripheral
blood lymphoid-cells (PBLC) obtained from the cancer-bearing rats. A significant cytotoxicity was
found to be expressed by the PBLCs, suggesting that during the development of mesothelioma, a
cellular retrodifferentiation occurs, thereby educating the effectors to recognize a common determi-
nant existing in both the tumor and fetal cells. Educated PBLCs were produced from rats having en-
dodermal tissue cancers (adenocarcinomas of the small bowel, colon and pancreas) and were found
to also be cytotoxic to the fetal cultures, yet no injury was apparently inflicted upon cultured meso-
thelioma target cells by these effectors. These results suggested that the tumor education was spe-
cific and that probably a unique and different fetal component was being recognized by the effector
cells obtained from the rats with lesions arising either in the mesodermal or endodermal tissue. Fur-
ther support for this concept was the failure of an antibody, specific to an oncofetal protein existing
in endodermal lesions, to apparently recognize any common oncogenic proteins in the mesothe-
lioma. Preliminary studies have also been accomplished which suggests the existence of natural kill-
ing immune responses existing to the mesothelioma target cells. These results, in contrast to other
recently reported findings, certainly intimate that asbestos-induced mesothelioma indeed results in
host antitumor immune responses and that immune therapy along with immunodiagnosis may in ac-
tuality prove to serve an important clinical role in the management of this form of cancer.
Introduction
Numerous biochemical and immunological studies
accomplished during the past two decades have ex-
tensively documented a close relationship existing
on the molecular level between the degree of cellu-
lar differentiation and cancer. It was reported in
these multifarious studies that cancer cells often
possessed many of the molecular properties only as-
sociated with the fetal state, thus leading Uriel (1, 2)
to postulate that cellular differentiation occurring
during ontogeny and retrodifferentiation existing in
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cancer represents an inverse sequence of nucleocy-
toplasmic events. This resulting expression of fetal
characteristics by cancer cells arising in the adult
was proposed to represent an alternative of two
convergent directions of a single chain ofpotentially
reversible events. Consequently in comparison, the
differentiation of a stem cell and retrodifferentia-
tion of a tumor could be assumed traveling through
similar stages of nucleocytoplasmic expression, al-
though in an opposite sequence. This process of can-
cer being a state of retrodifferentiation has been
proposed to be a means for morphological and func-
tional simplification which would uniformize origi-
nally distinct cell phenotypes and lead to a lower de-
pendency by the tumor on environmental require-
ments. (3).STEVENSETAL.
Furthermore, it has been postulated that the de-
velopment of fetal characteristics by a tumor is a
method whereby the malignant cells, like the fetus,
might escape immunological destruction being lev-
ied upon it by the host (4).
The concept of cancer possessing expressed fetal
characteristics while being silent in normal adult
differentiated cells has been extensively pursued in
an attempt to develop a bioassay for identification
of the disease. One of the most widely investigated
fetal proteins found existing in cancer has been the
carcinoembryonic antigen (CEA), a glycoprotein
originally isolated from human colorectal tumors
nearly 17 years ago(5, 6).
The concentration of this oncofetal protein has
been utilized under a variety of circumstances to
evaluate clinically both tumor recurrences and the
responses to palliative surgery, radiotherapy and
chemotherapy of patients having various forms of
cancer such as of the colon, pancreas, stomach, bi-
liary tract, breast, cervix, body of the uterus, ovary,
lung, and neuroblastoma (7, 8). However, recently an
analogous study of patients having mesothelioma
failed to detect the presence of any carcinoembry-
oniclike material existing in such tumors (9). The in-
vestigators concluded that one possible explanation
for the lack of CEA being present in such malignant
cells was that ontogenetically, mesothelium and en-
doderm are quite different tissues; consequently,
the antibody that was specifically generated to rec-
ognize the endodermal (colon) lesions might thus
have failed to identify the mesothelioma embryonic-
like components. We have recently focused our ef-
forts upon an attempt to establish whether such re-
trodifferentiation as seen in many other forms of
cancer might also occur in the asbestos induced ani-
mal model of mesothelioma. Our findings now indi-
cate that rats having such tumors possess immuno-
logically educated peripheral blood lymphoid-cells
(PBLCs) capable of recognizing fetal cells, thus sug-
gesting that mesothelioma does undergo a retroge-
netic expression and a further search for fetal
characteristics as possible tumor markers would be
warranted.
Materials and Methods
Tumor Induction
Young adult (200-250 g) male inbred Fischer F344
rats (F344/COBS CD F/CrL BR) were obtained from
Charles River Breeding Labs (Wilmington, MA) and
provided with commercial laboratory food (Purina
Rat Chow) and water ad libitum. Tumors were in-
duced by the weekly intraperitoneal injection of 25
mg for 4 weeks (total= 100 mg) of a saline suspen-
sion of International Union Against Cancer (UICC)
standard reference Canadian chrysotile B, kindly
provided by the Medical Research Council, Johan-
nesburg, South Africa. The control animals were
similarly injected with a saline suspension of Norite
A carbon decolorizing (Fisher Scientific Co., Fair-
lawn, NJ) and a second group classified as normal
rats were exposed to saline only.
Cell Cultures
Primary cell cultures were prepared from 6- to
10-day-old rat fetuses obtained from pregnant
Fischer animals. The fetuses were removed under
aseptic conditions, washed three times in 100 mL of
50mM phosphate-buffered saline (PBS, pH 7.4) con-
taining 100 U penicillin-streptomycin (Grand Island
Biological Co., Grand Island, NY), and were finely
minced with a sharp scalpel in the culture media
consisting of Ham's F-10 containing 10% heat-inacti-
vated fetal calf serum and 100 U penicillin-strepto-
mycin. The tissues were then placed in T-25 Falcon
tissue culture flasks (Falcon Division of Becton Dick-
inson and Co., Oxnard, CA) and the cells were al-
lowed to attach and grow in a humid 95% air-5%
CO2 atmosphere at 37°C. After 5 days, the media
and debris were decanted and fresh growth media
added to the flask. Confluent layers of cells were
regularly obtained within 3 weeks.
Cytotoxicity Assay
The cell-mediated immunity (CMI) was evaluated
by quantitating the increased release of radioiodi-
nated peripheral and integral membrane proteins of
injured and killed fetal cells brought about by sensi-
tized PBLCs obtained from the test rats as com-
pared with the designated controls. The procedure,
which has previously been described in detail (10),
consists of the following steps: single fetal cells
were obtained from the cultures by treatment with
0.25% trypsin in the PBS at 37°C for 5-20 min. A
3.7 MBq (100 pCi) aliquot of carrier-free'^I-Na
(Amersham, Arlington Heights, IL), 6.2 nmole of lac-
toperoxidase (Sigma Chemical Co., St. Louis, MO),
and 100 nmole of H202 in 1 mL PBS were sequen-
tially added to 2-3 x 106 fetal cells contained in 1 mL
of the PBS and the mixture allowed to incubate for
10 min. The reaction was quenched by the addition
of culture media, and the cells were then washed six
times with 35 volumes of the media through centri-
fugation at 400g for 15 min in order to remove any
unbound radioiodine. Following the final wash, the
cells were resuspended to a concentration of 6 to
16x 103 cells/mL and a 500 IAL aliquot placed in each
of 24 wells of a Falcon 3008 multiwell test plate.
This enzymatic labeling procedure represents a
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very mild method for in vitro radioiodination, as
generally greater that 90% viability (trypan blue
staining) and 70% to 80% plating efficiency have
been observed for the target cells. Spontaneous re-
lease was less than 10% over the 18-hr study inter-
val.
Effector lymphoid cells were obtained from a
freely bleeding tail vein of the animals, and the
PBLCs were partially purified by sedimentation
through a Ficoll-Hypaque gradient (Gallard-Schlesin-
ger, Carle Place, NY) according to the procedures
described by Boyum (11). The PBLCs were washed
with 5 mL of PBS and suspended in the culture me-
dia at a lymphoid cell:target cell ratio of 100:1 (6 to
16 x 105 effector cells/mL). A 500 .L aliquot of the ef-
fector cells was then added to each well of the
plated target cells according to the experimental de-
sign for best statistics as described by Brown and
co-workers (12). Eighteen hours later, three 150 ,L
samples were removed from each well, and the
quantity of iodine-125 released in the form of radio-
labeled membrane proteins from the injured and
dead target cells was determined by using a Beck-
man 4000 gamma counter (Beckman Instruments,
Irvine, CA). Cytotoxicity was calculated according
to the following formulas:
Natural CMI =
Tumor CMI = -
(Ec+T-I(T
(T)
(ET + T) - (E, + T)
(E + T)
x 100
x 100
where the released radioactivity is determined
under the designated conditions, with ET, EC being,
respectively, the effector PBLCs isolated from the
mesothelioma and control rats and T represents the
radioiodinated target cells. Significance was estab-
lished by application of a single-tailed Student's t-
test.
Results and Discussion
Several studies that have been reported during
the past 6 years have noted that mesothelioma cells
apparently fail to elicit host antitumor immune re-
sponses. For example, Embleton and colleagues (13)
were unable to detect any cell-mediated immunity
using target cultures derived from pleural effusions
of patients with pleural mesothelioma and mononu-
clear effector cells from such individuals. Similarly,
Brown et al. (14) reported that asbestos-induced
transplantable rat mesothelioma cells do not exhibit
tumor-associated transplantation antigens. This was
deduced by the failure of such cells to bring forth
immune responses capable of inhibiting subsequent
growth of the transplantable mesothelioma upon re-
challenge. It was concluded that this work sup-
ported the concept that tumors of long latent peri-
ods fail to stimulate host rejection through cell-sur-
face expression of tumor-associated transplantation
antigens. In contrast, our recent studies have sug-
gested that such cancer cells do indeed have proper-
ties capable of inducing host immune responses,
based upon our observations of cell-mediated immu-
nity in rats having intraperitoneal asbestos-induced
mesothelioma (15). Several factors among the exper-
iments could account for the different observa-
tions, such as the method for establishing immunity,
whether or not a primary or transplantable tumor
model was being investigated, and so forth.
Our current findings now indicate that these so-
called tumor-educated PBLCs that are obtained
from the asbestos-exposed rats are capable of recog-
nizing in addition to cancer cell components, fetal
characteristics as distinguished by significant CMI
being expressed towards fetal target cells (Table 1).
We contrasted the ability of these effector cells to
lyse the fetal cells to two different controls: rats ad-
ministered charcoal particulate and those injected
with isotonic saline. The total CMI expressed is not
significantly different when comparing these two
types of controls. The charcoal-exposed animals
were not seen to possess PBLCs capable of exhibit-
ing any different measurable lytic responses toward
such targets when contrasted to the saline exposed
rats (Table 2). These observations might possibly be
interpreted as the education of PBLCs toward some
type of a cellular component which is similar in both
the asbestos-induced neoplastic cells as well as ex-
isting normally in the fetal cells, i.e., a retrogenetic
expression might have occurred in the mesothe-
lioma.
Table 1. Cell-mediated immunity expressed towards
rat fetal cells by peripheral bloodlymphoid cells obtained from
rats bearing asbestos-induced mesothelioma.
CMIa
Animal Charcoal Saline
1 3.3 0.7 6.6 0.6
2 9.2±0.7 14.0±1.1
3 3.8 0.8 2.4 0.9
4 4.9 1.0 1.3 0.6
5 13.3±0.5 --
Total 6.9 1.9 6.1 2.9
aIndividual values represent the mean ± SD (N = 36); total
is the mean ± SE for the individual animals. CMI calculated by
the differences in observed release occurringin the presence of
PBLCs from the test compared tocharcoal-exposed rats or test
compared to normal saline-injected rats. The differences were
significant top < 0.01 for all of the individual test rats as com-
pared to their designated controls.
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On the basis of our previous studies (16) and the
present results, we believe that tumor-bearing rats
with both gastrointestinal lesions and asbestos-
induced mesotheliomas all possess PBLCs generally
capable of recognizing fetal cells (Table 3). Appar-
ently, there is a definite specificity that is exhibited
by such effectors toward tumor targets, with those
effectors obtained from animals having GI tumors
(small bowel, colon, pancreas) capable of recognizing
only tumor targets derived from endodermal lesions
and the PBLCs acquired from rats with mesothe-
lioma recognizing solely the mesodermal-derived
targets (Table 4). A large CMI difference was mea-
sured for the tumor-bearing rat responses because
the animals in the study were not controlled with
regards to their tumor burden; however, exact com-
parisons were made to the corresponding controls
with regard to age, size, time since exposure, etc.
Consequently, the reported errors appear large for
group comparisons, but between individual tumor
and its specific control, the CMI was always signifi-
cant to greater than a p < 0.01 level. During the
past several years, there have been numerous stud-
ies documenting the existence of natural cell-medi-
ated cytotoxicity to tumor cells in mice, rats, and
humans (17). The subpopulation of lymphocytes
found to be responsible for this natural resistance to
cancer have been termed NK (natural killer) cells
Table 2. Cell-mediated immunity expressed towards
rat fetal cells by peripheral blood lymphoid cells
obtained from rats exposed to charcoal.
Animal CMIa
1 0.0
2 0.7±0.7
3 0.0
4 0.0
5 0.7±0.5
Total 0.3 ± 0.2
a#jytotoxicity was calculated by the quantity of radioiodi-
nated membrane proteins of the fetal target cells brought
about by effector cells obtained from rats exposed to charcoal
particulate as compared to animals injected with saline only.
Individual values represent the mean ± SE (N = 36); total ex-
presses the mean ± SE for the individual animals.
(18). Our studies now indicate that such NK effects
are also expressed towards mesothelioma target
cells (Table 5). While we are currently establishing
whether NK cells in addition exert such cytotoxic-
ity towards fetal cells, we can eliminate their contri-
bution to the present results. This is because, in the
definition that we have applied for tumor CMI, the
NK levels are eliminated through subtraction:
Tumor CMI =
[(specific tumor effects + NK) - (NK effects)]
(NK effects)
Consequently, the values we are now reporting
represent increased specific effects brought about by
the effector cells obtained from the rats having
mesothelioma. Two interpretations can be offered
for the fetal cell destruction. One is that the target
cells consisted of a mixture containing both endoder-
mal and mesodermal cells, each type having its own
unique fetal characteristic common only to that spe-
cific type of tumor. A second explanation could be
thatthe effectors were educated torecognize at least
two types of cellular components, one found only
associated with that specific form of cancer while a
second was common to all fetal cells.
In an attempt to differentiate between these two
Table 3. Cell-mediated immunity expressed towards fetal
target cells by peripheral blood lymphoid cells
obtained from various tumor-bearing rats.
Effector cell source
(tumor model)a CMIb
Small bowel 7.4 2.1 (N = 4)
Colon 15.1 3.1 (N = 3)
Pancreas 17.9 6.1 (N = 3)
Mesothelioma 6.5 1.6 (N = 9)
aEffector cells were obtained from rats having adenocarci-
nomas induced in the small bowel by X-rays (22); in colon by
1,2-dimethylhydrazine (23); in pancreas by implantation of
7,12-dimethylbenz[a]anthracene (24); and in mesothelioma by
the intraperitoneal exposure to asbestos.
bValues represent mean ± SE of a group ofN animals uncon-
trolled for tumor burden. Each tumor-bearing rat had signifi-
cant (p < 0.01) CMI compared to its designated control.
Table 4. Cell-mediated immunity expressed towards tumor target cells by peripheral blood lymphoid cells
obtained from tumor-bearing rats.
Effector cell source
Tumor (tumor model)a
target cells Small bowel Colon Pancreas Mesothelioma
Small bowel 20.5 ± 8.3 (7) 21.9 ± 19.6(6) 0.0 ± 0.06 T)
Colon 8.8 ± 4.0 (7) 12.8 ± 6.5(8)
Pancreas 7.4 ± 2.8 (7) - 7.7 ± 3.1 (6) 0.0 ± 0.07 (5)
Mesothelioma 0.0 ± 0.15(2) 0.0 ± 0.04 (7) 0.0 ± 0.09 (8) 9.5 ± 2.6 (3)
aAdenocarcinomas were induced in the designated tissues as described in Table 3. Values represent the mean ± SE of a group
ofN rats uncontrolled for their tumor burden.
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Table 5. Natural cell-mediated immunity of saline control rats
expressed to asbestos-induced mesothelioma target cells.
Animal CMIa
1 26.3 ± 0.5
2 11.2 ± 0.4
3 2.3± 0.3
4 8.7± 1.7
5 17.9 ± 0.6
6 31.2 ± 0.5
Total 16.2 ± 4.5
aValues represent the mean ± SD (N = 36) of individual
animals while the total expressed the mean ± for the individ-
ual animals.
explanations, we have been utilizing a xenogenic an-
tiserum that specifically recognizes a common tumor-
associated fetal antigen existing only in endodermal
lesions (19-21) in a search for similar fetal
proteins in mesothelioma. At the present time, we
have been unable to demonstrate that such anti-
bodies are capable of recognizing any such compo-
nents in the asbestos-induced lesions. Certainly, the
failures to date may simply be the result of onco-
fetal concentration differences and of the titer of
the antiserum being such that it is incapable of de-
tecting these fetal proteins in mesothelioma; for this
reason a monoclonal antibody to the endodermal on-
cofetal protein is presently under preparation. It is
also very possible that the educated effector cell
specifically recognizes a component common solely
to the tumor and its fetal cell counterpart; as a con-
sequence, the general fetal cell cytotoxicity may be
due simply to a mixture of cell types in the target
culture. Wang and co-workers (9) similarly had re-
ported they were unable to detect any CEA in
patients with mesothelioma when employing an an-
tiserum generated to a colon tumor component. We
believe, based upon the results of these studies,
that the failures can most likely be attributed to the
type of antiserum utilized, and that with the devel-
opment of the appropriate antibodies generated to
the mesothelioma, rather than endodermal cancers,
then fetal components will be identified.
Additional evidence has now been provided in
this study to implicate a role for antitumor immune
responses both specific and nonspecific to asbestos-
induced mesothelioma in the rat. There appears to
be a retrogenetic expression occurring in the cancer
cells as shown by the capability of tumor-educated
effector cells to injure normal fetal cells. Whether
this represents a general phenomenon for all meso-
dermal derived tumors remains to be elucidated,
and we currently are pursuing similar investiga-
tions with other such cancers. Although our work is
still inconclusive, we believe that it is quite pre-
mature to discount utilizing immunodiagnosis or im-
munotherapy for patients with mesothelioma.
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